Abstract | BACKGROUND: METHODS: RESULTS: Treatment with MP and TAO resulted in a clear reduction in respiratory symptoms, asthmatic attacks, corticosteroid and hospitalization requirements, improvement in pulmonary function tests, and a remarkable decrease in peak expiratory flow rate circadian variability when compared with the period before TAO treatment (with corticosteroids). Treatment with MP and TAO was fairly well tolerated. Only a reduction (-5.2%, p < 0.01) in bone mineral content and an increase in plasma glucose levels (from 81.7 to 94.3 mg/dl, p < 0.05) were found, in comparison with pre- TAO values. One subject discontinued MP- TAO treatment because of a mild but persistent increase in serum alanine aminotransferase. In an evaluation of the clinical and pulmonary function test results, eight of the 14 subjects were responders and six were nonresponders. During follow-up three subjects discontinued TAO and consequently had an asthmatic attack after 4, 7, or 15 days, respectively. CONCLUSIONS: This study confirms that treatment with MP and TAO has a beneficial effect in a subgroup of severely steroid-dependent asthma patients.
|
Authors | A Siracusa, G Brugnami, T Fiordi, S Areni, C Severini, A Marabini |
Journal | The Journal of allergy and clinical immunology
(J Allergy Clin Immunol)
Vol. 92
Issue 5
Pg. 677-82
(Nov 1993)
ISSN: 0091-6749 [Print] United States |
PMID | 8227858
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Troleandomycin
- Methylprednisolone
|
Topics |
- Asthma
(drug therapy)
- Drug Therapy, Combination
- Drug Tolerance
- Female
- Humans
- Male
- Methylprednisolone
(therapeutic use)
- Middle Aged
- Smoking
- Troleandomycin
(therapeutic use)
|